

Programme ONCOPOLE – Avis d'intention admissibles

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
01	Development of precision therapeutic vaccines against myeloid leukemias.	Cancer immunotherapy, mass spectrometry, phosphatases, vaccines, bioinformatics, tumor-specific antigens.	Claude Perreault	Université de Montréal	Institut de recherche en immunologie et en cancérologie IRIC
02	Using big data to measure the costs and benefits of high-quality colorectal cancer care in Quebec.	Colorectal cancer, cancer care quality, patient-centred care, costs, clinical variation, administrative health data.	Erin Strumpf Geetanjali Datta	Université McGill Université de Montréal	Dept. of Economics, Dept. of Epidemiology, Biostatistics and Occupational Health Centre de recherche du CHUM
03	Eliminate tumor cells infiltrated into the brain using a radioactive matrix.	Brain tumor, Radiotherapy, Chemoattractant, Hydrogel, Radioisotope.	Nathalie Fauchoux	Université de Sherbrooke	Département de génie chimique et de génie biotechnologique
04	Optimizing care for castration-resistant prostate cancer patients using dual-tracer molecular imaging and targeted radioligand therapy.	Castration-resistant prostate cancer (CRPC), Positron emission tomography imaging, Targeted radioligand therapy, Dual-tracer 68Ga-PSMA/68Ga-Octreotate, Inpatient intermetastasis polyclonality, Early recurrence CRPC.	Brigitte Guérin Frédéric Pouliot Jean-Mathieu Beauregard	Université de Sherbrooke Université Laval Université Laval	Sherbrooke Molecular Imaging Center, CRCHUS CHU de Québec Centre de recherche CHU de Québec
05	Novel strategies to prime cancer immunotherapy.	Mesenchymal stem cells, Immunoproteasome, Cross-presentation, Immune checkpoint inhibitors, Nociceptor modulation, Exosomes.	Mouthih Rafei Sébastien Talbot	Université de Montréal Université de Montréal	Dept. of Pharmacology and Physiology Dept. of Pharmacology and Physiology

#	Titre du projet	Mots-clés	Équipe				
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)		
06	Collective governance in the Quebec Cancer Network: a realist evaluation of emerging mechanisms of institutionalization, multi-level governance and value creation using a longitudinal multiple case study design.	Governance, costs analysis, expérience de soins des patients, Resources use, Étude de cas longitudinale, Realistic evaluation.	Dominique Tremblay	Université de Sherbrooke (Campus de Longueuil)	Centre de recherche de l'Hôpital Charles-Le Moyne (CRHCLM)		
			Nassera Touati			École nationale d'administration publique (ENAP) (Montréal)	Centre de recherche de l'Hôpital Charles-Le Moyne (CRHCLM)
07	Targeting the DNA Damage Response for Novel Anti-Cancer Therapy.	DNA repair, DNA damage response, Synthetic lethality, Non-oncogene addiction Radiotherapy, Chemotherapy.	Alain Nepveu	Université McGill	Goodman Cancer Research Centre		
			Anne Marinier			Université de Montréal	Institut de recherche en immunologie et en oncologie IRIC
			Alexandre Orthwein	Université McGill	Institut Lady Davis		
08	Developing precise management strategies involving new DNA repair targeted chemotherapies for women with ovarian cancer	Ovarian cancer, Genetic testing, Cancer predisposition, Precision medicine, Chemotherapy response, DNA repair pathways.	Patricia Tonin	Université McGill	Research Institute -MUHC		
			Walter Gotlieb			Université McGill	Segal Cancer Center, Jewish General Hospital
			Ioannis Ragoussis			Université McGill	Genome Quebec Innovation Centre
09	The role of lifestyle factors and patient engagement on improving ovarian cancer prognosis	Ovarian cancer, Lifestyle Physical activity, Diet, Patient engagement, Prognosis.	Anita Koushik	Université de Montréal	Centre de recherche du CHUM		
			Marie Plante			Université Laval	CHU de Québec
			Marie-Pascale Pomey	Université de Montréal	Centre de recherche du CHUM		

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
10	Development of a digital health tool for management of chemotherapy and targeted therapy side effects.	Cancer, chemotherapy, targeted therapy, self-management, application, quality of life.	Julie Lemieux Marie-Pierre Gagnon	Université Laval Université Laval	Centre de recherche du CHU de Québec Faculté des sciences infirmières
11	Identifying molecular markers of aggressive breast lesions with a high likelihood of progressing to invasive breast cancer.	Cancer du sein, lésions mammaires, biomarqueur données –omiques, apprentissage machine, continuum de risque/prévention	Francine Durocher	Université Laval	Centre de recherche du CHU de Québec
12	Identifying individuals at-risk for hereditary cancers using a decision support tool integrated into the Electronic Medical Record of Family Medicine Groups: Proof of concept.	Hereditary cancers, screening, genetic testing, tool development, primary healthcare, prevention.	Michel Dorval Hermann Nabi Pavel Hamet	Université Laval Université Laval Université de Montréal	Centre de recherche du CHU de Québec Centre de recherche CHU de Québec Centre de recherche du CHUM
13	A Phase 1/2 study of Trametinib for pediatric neuro-oncology patients with refractory tumor and activation of the MAPK/ERK pathway.	Trametinib, glioma, plexiform neurofibroma, pediatric , MEK.	Sébastien Perreault	Université de Montréal	CHU Ste-Justine
15	Novel Combinatorial Immunotherapy for Pancreatic Ductal Adenocarcinoma.	Pancreatic ductal adenocarcinoma, immunotherapy, IGF, liver metastasis, combinatorial therapy, tumor microenvironment.	Pnina Brodt	Université McGill	Research Institute MUHC
16	Deciphering lung development to understand and treat pediatric lung cancer.	YY1, microRNA, FGF10, Mouse models, Pediatric lung cancer, DICER1 syndrome.	Lucie Jeannotte	Université Laval	Centre de recherche du CHU de Québec

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
17	Third-party Human Umbilical Cord Perivascular (HUCPV)-derived Mesenchymal Stromal Cells (MSC) to Treat Refractory or Steroiddependent Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Children.	Leukemia, aGvHD, Mesenchymal Stem Cells, Umbilical Cord.	Henrique Bittencourt  Denis-Claude Roy	Université de Montréal  Université de Montréal	Centre de recherche du CHU Sainte Justine  Hôpital Maisonneuve-Rosemont
18	Partnership initiative for the Evaluation of technological innovation in Radiotherapy (PERA).	Clinical Trial, Randomized, Registry, Radiotherapy, Technology, Patient-Reported Outcomes.	Cynthia Ménard	Université de Montréal	Centre de recherche du CHUM
19	Establishing a chemogenomic screening pipeline for high risk acute pediatric leukemias.	Acute leukemias, Chemogenomic, Human model system, CRISPR, High throughput screening, Drug discovery.	Brian Wilhelm  Frédéric Barabé  Sonia Cellot	Université de Montréal  Université Laval  Université de Montréal	Institut de recherche en immunologie et en oncologie IRIC  Centre Hospitalier de l'Université Laval (CHUL)  CHU Sainte-Justine
20	Using Single-Cell Epigenomics for Clonal Dynamics and Prognostic Risk Characterization in Pediatric and Young Adult Sarcoma Patients.	Pediatric and young adult sarcoma, Single-cell epigenomic profiling, Tumor clonal dynamics, Tumor microenvironment, Response to treatment, Prognostic risk biomarker signature.	Daniel Sinnett  Nada Jabado  Guillaume Bourque	Université de Montréal  Université McGill  Université McGill	Centre de recherche du CHU Sainte-Justine  Research Institute MUHC  Génome Québec Innovation Centre
21	Improving quality of life of women in chemotherapy for breast cancer: A cost-utility analysis of Telehealth to improve adherence to physical exercises.	Cost-utility, Breast cancer, Quality of life, Fatigue, Physical activity, Telehealth.	Michel Tousignant  Thomas Poder	Université de Sherbrooke  Université de Sherbrooke	Centre de recherche sur le vieillissement (CdRV)  Centre de recherche du CHUS

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
22	Targeting Tumour-Microenvironment Interactions that Control Breast Cancer Initiation, Dormancy, and Recurrence.	Breast cancer, Cancer initiation, Immuno-Oncology, Transgenic mouse models, Tumour dormancy, Ductal carcinoma in situ.	William Muller	Université McGill	Goodman Cancer Research Centre (GCRC)
			Luke McCaffrey	Université McGill	Goodman Cancer Research Centre
			Jean-François Côté	Université de Montréal	Institut de recherches cliniques de Montréal (IRCM)
23	Quantitative and multiplexed immunoplasmonics for cancer diagnosis.	Cancer, Biomedical technology, Pathology, Plasmonic nanoparticles, Cytology, Human health.	Michel Meunier	École Polytechnique de Montréal	École Polytechnique de Montréal
			Dominique Trudel	Université de Montréal	CHUM
			Louis Gaboury	Université de Montréal	Institut de recherche en immunologie et en oncologie IRIC
24	Multidisciplinary approach for the therapeutic targeting of hard to treat cancers with new anti-cancer and anti-inflammatory therapies.	Thérapies combinées.,Nouvelles avenues thérapeutiques, Cancer de la vessie, Cancer du sein de type triple-négatif, Cancer du poumon, Cancer du côlon.	Isabelle Plante	INRS	INRS-Institut Armand-Frappier
			Jean Legault	Université du Québec à Chicoutimi	Département des sciences fondamentales
25	Targeting genome instability as an essential vulnerability in ovarian cancer.	DNA damage response, high-grade serous ovarian carcinoma, Ran GTPase, cell fate, PARP inhibitors, cellular senescence.	Anne-Marie Mes-Masson	Université de Montréal	Centre de recherche du CHUM
			Francis Rodier	Université de Montréal	Centre de recherche du CHUM
			Jean-Yves Masson	Université Laval	Centre de recherche du CHU de Québec

#	Titre du projet	Mots-clés	Équipe			
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)	
26	All4ALL: fighting Acute Lymphoblastic Leukemia (ALL) together in Quebec.	All4ALL (Acute lymphoblastic leukemia), onco/pharmacogenomics, therapeutic drug monitoring, immune therapies, liquid biopsy, cancer biomarkers.	Jean-Marie	Leclerc	Université de Montréal	CHU Ste-Justine
			Maja	Krajnovoc	Université de Montréal	CHU Ste-Justine
			Julie	Bergeron	Université de Montréal	Hôpital Maisonneuve-Rosemont
27	Rationally designed approaches to target mRNA translation in eradicating poor outcome breast cancers.	mRNA translation, breast cancer, GEMM and PDX models, eIF4A inhibitor, eIF2a inhibitor, mTORC1 signaling.	Nahum	Sonenberg	Université McGill	Goodman Cancer Research Centre
			Josie	Ursini-Siegel	Université McGill	Lady Davis Institute for Medical Research
			Philippe	Roux	Université de Montréal	Institut de recherche en immunologie et en oncologie IRIC
28	Data-driven research and shared decision-making in prostate cancer.	Prostate cancer, Electronic consent, Data sciences/Machine learning, Clinical Decision Support Systems, Shared Decision-Making, Electronic Medical Records.	Philippe	Després	Université Laval	Centre de recherche du CHU de Québec
			Bartha Maria	Knoppers	Université McGill	Centre of Genomics and Policy
			France	Légaré	Université Laval	Centre de recherche du CHU de Québec
29	Development of a novel immunotherapy for bladder cancer based on the use of a novel TLR7/8 agonist.	Bladder cancer, Toll like receptor 7/8, Nanoparticles, Immunotherapy, Immune checkpoints, cold vs hot tumour.	Denis	Leclerc	Université Laval	Centre de Recherche en Infectiologie-CHU Québec
			Alain	Lamarre	INRS	Centre INRS-Institut Armand Frappier

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
30	Exploring T cell heterogeneity and understudied pathways to improve anti-cancer T cell therapies.	T cells, cancer immunotherapy, adoptive cell therapy, exhaustion, single cell RNA sequencing, CRISPR.	Nathalie Labrecque Martin Richer Heather Melichar	Université de Montréal Université McGill Université de Montréal	Centre de recherche Hôpital Maisonneuve-Rosemont Microbiology/Immunology Centre de recherche Hôpital Maisonneuve-Rosemont
31	e-IMPAQC: Implementation and evaluation of a mobile application for the realtime electronic assessment of cancer patient- and informal caregiver-reported outcomes to improve symptom burden and quality of life in Quebec.	Cancer, Electronic patient-reported outcomes, m-Health, Self-management, Symptom management, Quality of life.	Sylvie Lambert John Kildea David Roberge	Université McGill Université McGill Université de Montréal	CIUSSS ODIM - St. Mary's Research Centre Research Institute MUHC Centre de recherche du CHUM et CHUM
32	Création d'une plateforme d'immuno-évaluation et thérapeutique pour les patient atteints d'un myélome multiple.	Multiple myeloma, Immunotherapy, allogeneic stem cell transplant, Single cell RNA sequencing, cell therapy, Immune profiling.	Michael Sebag Richard LeBlanc	Université McGill Université de Montréal	MUHC Hôpital Maisonneuve-Rosemont
33	From Bench to Bedside: Novel Strategies to Screen and Treat Fatty Liver related Liver Cancer	Hepatocellular Carcinoma (HCC). Non-alcoholic liver disease (NAFLD). Imaging. Deep Learning. T cells. Innate Immunity.	Naglaa Shoukry Tang An Jennifer Estall	Université de Montréal Université de Montréal Université de Montréal et Université McGill	Centre de recherche du CHUM Centre de recherche du CHUM IRCM
34	Electronic record to optimize care throughout the complete trajectory of patients with cancer – a proof of concept.	Dossier numérique, Optimisation des parcours de soins, Étude de cohorte, Infirmière praticienne spécialisée, Coordination des soins, Recherche évaluative.	Aude Motulsky Tibor Schuster	École de santé publique de l'U de M Université McGill	Centre de recherche du CHUM Faculté de médecine, département de médecine familiale

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/ Département (s)
35	Bridging fundamental research to nutritional, physical activity and clinical interventions in colorectal cancer prevention.	Colorectal cancer (CRC) prevention, Anticancer nutripventive diet, Exercise training, Post-polypectomy, Healthy lifestyles, Cancer recurrence.	Borhane Annabi	UQAM	Centre de recherche BIOMED, Chaire en Prévention et Traitement du Cancer
36	Patient stratification for Anti-Angiogenic Therapies : prognostic and drug screening markers.	Liver metastases, vessel co-option, angiogenesis, patient stratification, imaging, liquid biopsies.	Peter Metrakos	Université McGill	Research Institute MUHC
			Janusz Rak		
37	Lipidomics and its application to Colorectal Cancer Liver Metastasis (CRCLM): Innovative tools for risk assessment.	Mass spectrometry, Lipids, Biomarkers, Cancer, Liver.	Pierre Chaurand	Université de Montréal	Département de Chimie
38	Determining the best training modality during systemic cancer treatment to reduce cancer-related fatigue and treatment-induced side effects: a multicentric Quebec study.	Aerobic training, Mixed training, High-intensity interval training, Cancer-related fatigue, Cardiorespiratory and functional capacity, Cardiac dysfunction.	Michel Pavic	Université de Sherbrooke	Centre de recherche du CHUS
			Eléonor Riesco		
			Mathieu Gayda	Université de Montréal	Institut de Cardiologie de Montréal
39	Stand-up-for-the-cure: Novel approaches toward innovative therapeutic options for the treatment of solid tumours in the advanced stages.	Multitargeted drugs, Polypharmacology, Tumour microenvironment, Cell signaling, Stem cells, Antibody-drug conjugate (ADC).	Bertrand Jean-Claude	Université McGill	Research Institute MUHC
			René C.- Gaudrault		
			Bassam Abdulkarim	Université McGill	Research Institute MUHC



#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
40	Using transcriptome analysis and cellular deconvolution to improve biopsy performance, prognostic power, and treatment stratification in prostate cancer.	Transcriptomics, biopsy, prognostic signature, treatment stratification, cell deconvolution, immune cells.	Axel Andreas Thomson Étienne Gagnon	Université McGill Université de Montréal	Research Institute MUHC Institut de recherche en immunologie et en oncologie IRIC
41	More Organ Preservation : High dose rate brachytherapy versus External beam radiation therapy Multicenter Study Proposal (Morpheus) – A randomized phase III study.	Organ Preservation, Watch and Wait, No surgery.	Té Vuong	Université McGill	Jewish General Hospital
42	Novel approaches to prevent and lessen immunosuppression in allogeneic stem cell transplant recipients with chronic GVHD.	Stem cell transplantation, graft-versus-host disease, immune reconstitution, cytokines, microvesicles, lymphocytes.	Martin Guimond Jean Roy	Université de Montréal Université de Montréal	Centre de Recherche de l'hôpital Maisonneuve-Rosemont Centre de Recherche de l'hôpital Maisonneuve-Rosemont
43	Exploiting metabolic and oxidative stress responses to prevent or overcome the therapeutic resistance in breast cancer.	Breast cancer, metabolomics, oxidative stress, Tumor metabolism, targeted therapies, PDX models.	Morag Park Michael Pollak Sylvie Mader	Université McGill Université McGill Université de Montréal	Goodman Cancer Research Centre Lady Davis Institute for Medical Research / Segal Cancer Centre Institut de recherche en immunologie et en oncologie IRIC
44	Comprehensive molecular and clinico-epidemiologic characterization of lethal prostate cancer in Quebec: Analysis of the prospective cohort of the PROCURE Biobank.	Prostate cancer, PROCURE biobank, Tumor profiling, Immune landscape, Liquid biopsies, Diet-Obesity-Epidemiology.	Armen Aprikian Simone Chevalier Fred Saad	Université McGill Université McGill Université de Montréal	MUHC Research Institute MUHC CHUM

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
45	Gut Microbiome Regulation of the Tumor Microenvironment and Interactions with Diet and Concurrent Medication: Prognostic and Therapeutic Implications for Immunotherapy of Non-Small Cell Lung, Renal Cell and Urothelial Cancers.	Biobank of clinical data and biological samples, PD-1/PD-L1 Immunotherapy, Microbiota, Bladder-Kidney-and-Lung cancers, Liquid biopsies, Prognostic and theranostic biomarkers.	Yves Fradet Philippe Joubert Bertrand Routy	Université Laval Université Laval Université de Montréal	Centre de recherche du CHU de Québec Institut universitaire de cardiologie et de pneumologie de Québec Centre de recherche du CHUM
46	Comprehensive Assessment of the Androgen Metabolome in Metastatic Castration-Resistant Prostate cancer.	Metastatic Castration-Resistant Prostate Cancer, Determinants of drug response, Patients' survival, Steroid metabolome, Pharmacogenomics, Genomics.	Chantal Guillemette Louis Lacombe Éric Lévesque	Université Laval Université Laval Université Laval	CHU de Québec CHU de Québec CHU de Québec
47	CIIRAE: The Cancer Immunotherapies and Immune-Related Adverse Events Study.	Autoimmunity, Cohort study, T cell biology, Immune tolerance, Biomarkers.	Wilson Miller Ciriaco Piccirillo Marie Hudson	Université McGill Université McGill Université McGill	Jewish General Hospital-Lady David Research Institute Research Institute MUHC Jewish General Hospital-Lady David Research Institute
48	High-resolution mapping of cancer immunity for HER2-positive breast cancer patients during treatment.	Immuno-oncology, genomics, breast cancer, single-cell profiling, monitoring response to therapy, imaging.	Vanessa Dumeaux Réjean Lapointe	Université Concordia Université de Montréal	PERFORM Center Centre de recherche du CHUM
49	A novel adjuvant therapy for melanoma: the role of beta-blockers.	Ocular melanoma, adjuvant therapy, liquid biopsy, cutaneous melanoma, beta-blockers, animal model.	Miguel Burnier Goffredo Arena	Université McGill Université McGill	MUHC MUHC

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
50	Understanding and overcoming immune checkpoint blockade resistance in melanoma.	Melanoma, Immune checkpoint blockade resistance, CD73-adenosine, GSK-3, MNK1/2 inhibitors, Small molecule inhibitor (SMI) combination therapy.	Ian Watson Christopher Rudd John Stagg	Université McGill Université de Montréal Université de Montréal	Goodman Cancer Research Centre Centre de Recherche Hôpital Maisonneuve-Rosemont CHUM
51	ONCOPOLE: MicroRNA therapeutics team.	MicroRNA, Therapeutics, Target identification, MicroRNA chemistry, Delivery optimization, Preclinical testing.	François Major Jeanne Leblond-Chain Gerardo Ferbeyre	Université de Montréal Université de Montréal Université de Montréal	Institut de recherche en immunologie et en oncologie IRIC Fac. Pharmacie Dépt. biochimie et médecine moléculaire
52	Circulating DNA in Breast Cancer: a novel prognostic biomarker.	Liquid biopsy, prognosis, breast cancer, ctDNA, exosomes, biomarker.	Mark Basik Saima Hassan	Université McGill Université de Montréal	Lady Davis Institute Centre de recherche du CHUM
53	Therapeutic vulnerabilities in acute lymphoblastic leukemia.	Leucémie lymphoblastique aigue, Cellules souches leucémiques, Vulnérabilité thérapeutique, Interaction chimique et génétique, Biosenseurs.	Trang Hoang	Université de Montréal	Institut de recherche en immunologie et en oncologie IRIC
54	Development of minimally invasive tests to follow the progression of prostate cancer.	Cancer de la prostate, Génomique, Protéomique, Métabolomique, Progression du cancer, Biomarqueurs	Jacques Lapointe Étienne Audet-Walsh	Université McGill Université Laval	Research Institute MUHC Centre de recherche du CHU de Québec
55	Immunosuppression and cancer risk in solid organ transplantation recipients: A province-wide 20-year retrospective cohort study.	Cancer, transplantation, cohort study, immunosuppressants, registry.	Ruth Sapir-Pichhadze	Université McGill	MUHC

#	Titre du projet	Mots-clés	Équipe		
			Chercheur (s) principal (aux)	Université (s)	Institut (s)/Centre (s)/Département (s)
56	Interdisciplinary Management of Bone Metastases.	Bone metastases, Interdisciplinary management, Pharmacological Intervention, Rehabilitation Intervention, Skeletal Related Events, Pathological Fractures.	Thierry Muanza	Université McGill	MUHC
57	PRÉCISION-Q: PProspective moIECular proffling Strategies fOr paNcreatic cancer in Québec.	Pancreatic cancer, genetics, onco-genomics, homology-directed DNA repair, precision oncology, multi-centre.	George Zogopoulos Gerry Batist Mustapha Tehfe	Université McGill Université McGill Université de Montréal	RI-MUHC and Goodman Cancer Research Centre Lady Davis Institute (LDI) of the Jewish General Hospital Centre de recherche du CHUM